Clinical Trials in Rheumatology

Buch | Hardcover
772 Seiten
2011
Springer London Ltd (Verlag)
978-1-84996-383-1 (ISBN)

Lese- und Medienproben

Clinical Trials in Rheumatology - Ruediger Mueller, Johannes von Kempis
192,55 inkl. MwSt
zur Neuauflage
  • Titel erscheint in neuer Auflage
  • Artikel merken
Zu diesem Artikel existiert eine Nachauflage
With more than 400 extant studies in this field, a figure added to weekly, it can be hard to keep track of emerging trends. Covering all the studies so far published, this easy reference is for scientists and clinicians who deal with immunosuppressive drugs.
A huge number of therapeutic studies has been published in rheumatology and clinical immunology. This number grows substantially by the year. As such, it becomes increasingly difficult to keep track of this multitude of studies and the ensuing therapeutic trends. Further to this, a particular study can be referred to in a variety of ways, either as a shortened version of the title or an acronym, adding to the confusion. This book "Clinical Trials in Rheumatology" provides a summary of the important studies in the field for easy reference. Every study is shown with name, acronym (if in existence), authors, complete citation, study design, results, and summary. An acronym finder is supplied at the beginning of the book. This book is a valuable reference tool for rheumatologists and other clinical specialties, as well as for research scientists interested in immunomodulatory and selected other drug therapies in rheumatologic diseases.

Rudiger Muller, MD, is Senior Consultant in rheumatology at the Kantonsspital in St Gallen, Switzerland. Johannes von Kempis, MD, is the Head of the Rheumatology Division at Kanstonsspital in St Gallen, Switzerland.

Rheumatoid Arthritis:- Corticosteroids:- Atorvastatin:- Azathioprine:- Chloroquine/Hydroxychloroquine:- Ciclosporin:- Cyclophosphamide:- Gold:- Leflunomide:- Methotrexate:- Sulfasalazine:- Tacrolimus:- Combination Therapy:- Methotrexate and Hydroxychloroquine:- Methotrexate and Doxycycline:- Methotrexate and Sulfasalazine:- Methotrexate and Civlosporin:- Methotrexate and Hydroxychloroquine and Sulfasalazine:- Methotrexate and Leflunomide:- Methotrexate and Azathioprine:- Methotrexate and Gold:- Gold and Hydroxychloroquine:- Abatacept:- Adalimumab:- Anakinra:- Certolizumab pegol:- Etanercept:- Golimumab:- Infliximab:- Rituximab:- Tocilizumab:- Ankylosing Spondylitis:- Corticosteroids:- Cyclophosphamide:- Leflunomide:- Methotrexate:- Pamindronate:- Sulfasalazine:- Combination therapy:- Adalimumab:- Etanercept:- Golimumab:- Infliximab:- Psoriatic Arthritis;- Chloroquine/Hydroxychloroquine:- Ciclosporin:- Leflunomide:- Methotrexate:- Sulfasalazine:- Adalimumab:- Alefacept:- Etanercept:- Golimumab:- Infliximab:- Ustekinumab:- Systemic Lupus erythematosus:- Corticosteroids:- Azathioprine:- Chloroquine/Hydroxychloroquine:- Cyclophosphamide:- Leflunomide:- Methotrexate:- Mycophenolate mofetil:- Raloxifene:- Tacrolimus:- Combination:- Azathioprine + Ciclosporine:- Hydroxychloroquine and Mycophenolate mofetil:- Infliximab:- Rituximab:- Antiphospholipid Syndrome:- Aspirin vs. Heparin:- Heparin vs. Intravenous Immunoglobulins:- Prednisone + Aspirin:- Warfarin:- Progress. System Sclerosis:- Corticosteroids:- Ambrisentan:- Azathioprine:- Bosentan:- Chlorambucil:- Ciclosporin:- Colchicine:- Cyclophosphamide:- D-Penicillamine:- Methotrexate:- Mycophenolate mofetil:- 5-Fluorouracil:- Etanercept:- Infliximab: Rituximab: Plasma exchange:- Stem cell transplantation:- Raynaud,s phenomenon:- Bosentan:- Diltiazem:- Glyceryl Trinitrate:- Iloprost:- Nifedipine:- Sildenafil:- Dermato/Polymyositis:- Corticosteroids:- Cyclophosphamide:- Immunoglobulins:- Methotrexate:- Mycophenolate mofetil:- Anti-TNF:- Etanercept:- Rituximab:- Sjogren's syndrome:- Hydroxychloroquine:- Leflunomide:- Methotrexate:- Mycophenolate mofetil:- Pilocarpine:- Etanercept:- Infliximab:- Rituximab:- Takayasu arteritis:- Methotrexate:- Mycophenolate mofetil:- Anti-TNF:- Giant cell arteritis:- Corticosteroids:- Ciclosporin:- Methotrexate:- Etanercept:- Infliximab:- Polymyalgia rheumatica:- Corticosteroids:- Azathioprine:- Methotrexate:- Etanercept:- Infliximab:- ANCA-associated Vasculitis incl. trials combined with polyarteritis nodosa:- Azathioprine/:- Co-Trimoxazole:- Cyclophosphamide:- Methotrexate:- Mycophenolate mofetil:- Anti-thymocyte globulin:- Etanercept:- Immunoglobulin:- Infliximab:- Plasma exchange:- Purpura Schoenlein Henoch:- Corticosteroids:- Azathioprine:- Ciclosporine:- Cyclophosphamide:- Morbus Behcet:- Corticosteroids:- Azathioprine:- Ciclosporine:- Colchicine:- Cyclophosphamide:- Dapsone:- Methotrexate:- Mycophenolate mofetil:- Tacrolimus:- Thalidomide:- Etanercept:- Infliximab:- Interferon alfa-2a:- Acronyms:- Abbreviations:-

Zusatzinfo black & white illustrations
Verlagsort England
Sprache englisch
Maße 156 x 234 mm
Gewicht 1249 g
Einbandart gebunden
Themenwelt Medizinische Fachgebiete Innere Medizin Rheumatologie
Medizin / Pharmazie Medizinische Fachgebiete Pharmakologie / Pharmakotherapie
Medizin / Pharmazie Pharmazie
Studium 2. Studienabschnitt (Klinik) Pharmakologie / Toxikologie
ISBN-10 1-84996-383-5 / 1849963835
ISBN-13 978-1-84996-383-1 / 9781849963831
Zustand Neuware
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich

von Alexander Pfeil; Peter Oelzner; Joachim Böttcher

Buch | Softcover (2023)
Urban & Fischer in Elsevier (Verlag)
44,00
Information für Erkrankte, Angehörige und Betreuende

von Matthias Schneider

Buch | Softcover (2023)
Springer (Verlag)
22,99